Señales en vivo de IKT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Volumen de hoy	98 979.00
Volumen promedio	103 828
Capitalización de mercado	11.08M
EPS	$0 ( 2024-03-29 )
Próxima fecha de ganancias	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0260 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.53
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

Volumen Correlación

Largo: -0.10 (neutral)

Corto: -0.36 (neutral)

Signal:(46.053) Neutral

Inhibikase Therapeutics, Correlación

10 Correlaciones Más Positivas
SVOK	0.82

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inhibikase Therapeutics, Correlación - Moneda/Commodity

0.33
( neutral )

0.41
( neutral )

0.00
( neutral )

0.41
( neutral )

-0.10
( neutral )

-0.44
( neutral )

Inhibikase Therapeutics, Finanzas

Annual	2023
Ingresos:	$260 500
Beneficio Bruto:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
Ingresos:	$260 500
Beneficio Bruto:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
Ingresos:	$123 440
Beneficio Bruto:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
Ingresos:	$3.10M
Beneficio Bruto:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.